Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Investigational New Drugs|February 16, 2020
Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphologyOmar Abuhussein, Jian Yang
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2021
Identification of Synthetic Lethal Interactions Using High-Throughput, Arrayed CRISPR/Cas9-Based PlatformsMacKenzie J MacAuley, Omar Abuhussein, Frederick S Vizeacoumar
Cancers|October 17, 2020
The CINs of Polo-Like Kinase 1 in CancerChelsea E Cunningham, Mackenzie J MacAuley, Frederick S Vizeacoumar, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2021
Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction NetworksKalpana K Bhanumathy, Omar Abuhussein, Frederick S Vizeacoumar, et al.
Scientific Reports|April 23, 2017
Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screensMd Fahmid Islam, Atsushi Watanabe, Lai Wong, et al.
Gastro Hep Advances|January 5, 2026
Advancing Esophageal Disease Modeling: Microfluidic Platforms for Adult Tissue-Resident Stem Cell Culture and DifferentiationSara Hosseini-Farahabadi, Omar Abuhussein, Corina Stewart, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 9, 2025
A Reflux Linked GATA Factor Fulcrum Dictates Lineage Commitment Through GPRC5B During the Esophageal Dysplastic TransitionOmar Abuhussein, Sara Hosseini-Farahabadi, Corina Stewart, et al.
Oncotarget|August 25, 2016
Therapeutic relevance of the protein phosphatase 2A in cancerChelsea E Cunningham, Shuangshuang Li, Frederick S Vizeacoumar, et al.
Signal Transduction and Targeted Therapy|June 3, 2026
Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancersJared D W Price, Frederick S Vizeacoumar, Omar Abuhussein, et al.
Cell Genomics|May 10, 2025
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityChelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, et al.
Pageof 1